FDA Eases Path for New Diabetes Behavioral Devices
Published Date: 7/24/2026
Rule
Summary
The FDA has officially placed the diabetes digital behavioral therapeutic device into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification took effect on July 24, 2026, with benefits starting from July 7, 2023, making it easier and potentially cheaper for makers to bring these devices to market.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Special Controls: Clinical and Software Evidence
The final order requires design verification and validation that include clinical data from a "statistically and clinically justified sample size" and software verification, validation, and hazard analysis demonstrating the device performs as intended. The clinical data must validate the therapy model with a clinically defined endpoint and show the device does not adversely impact health outcomes.
Class II for Diabetes Therapy Software
The FDA classified the diabetes digital behavioral therapeutic device as Class II (special controls). The final order is effective July 24, 2026, and the classification was applicable on July 7, 2023. FDA says this classification will provide reasonable assurance of safety and effectiveness and may enhance patients' access by reducing regulatory burdens.
Enables 510(k) Predicate Pathway
By classifying this device into Class II via De Novo, FDA says that this device type can serve as a predicate for future devices. That means other device sponsors can use the less burdensome 510(k) process instead of De Novo or premarket approval for substantially equivalent devices.
510(k) Premarket Notification Still Required
FDA states that diabetes digital behavioral therapeutic devices remain subject to premarket notification under section 510(k). At this time, FDA has not determined that this device type is exempt from 510(k), so sponsors must submit a 510(k) to reasonably assure safety and effectiveness.
Labeling Must Include Clinical Summary and Limits
Labeling for these devices must include a summary of clinical testing and limiting statements. The label must say the device is not intended as a standalone therapy, is not a substitute for prescribed therapy or medication, should not be used by people with unstable psychiatric disorders, and is not intended to treat psychiatric disorders or symptoms.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14985, Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens
The FDA is officially putting over-the-counter COVID-19 tests into a safer, easier-to-manage category called Class II, starting July 24, 2026. This change helps make sure these tests work well and are safe, while also making it simpler for companies to bring new tests to you. If you’re a test maker or a user, expect better access and less red tape, with no extra costs announced.
2026-15021, Evonik Corporation, Filing of Food Additive Petition (Animal Use)
Evonik Corporation has asked the FDA to approve ethyl cellulose as a safe binder and coating for amino acids in food for ruminant animals like cows and sheep. This change could improve animal feed quality without extra costs or delays, with the petition officially filed on June 16, 2026. Farmers and feed producers should keep an eye out as this could soon become part of the rules.
2026-14984, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progression
The FDA is officially putting a special kidney disease test into Class II, meaning it’s safe and effective but with some extra rules to keep it that way. This change helps patients get access to this cool new test faster by cutting down red tape. The new classification is effective July 24, 2026, and could save companies time and money while making sure the test works well.
2026-14989, Francis Esteban Matos: Final Debarment Order
Francis Esteban Matos is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on July 24, 2026. Matos can apply to end this ban anytime, but he must follow specific rules to do so.
Previous / Next Documents
Previous: 2026-14985, Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens
The FDA is officially putting over-the-counter COVID-19 tests into a safer, easier-to-manage category called Class II, starting July 24, 2026. This change helps make sure these tests work well and are safe, while also making it simpler for companies to bring new tests to you. If you’re a test maker or a user, expect better access and less red tape, with no extra costs announced.
Next: 2026-14987, Medical Devices; Orthopedic Devices; Classification of the Intraoperative Surgical Angle Measurement Tool
The FDA is officially putting the intraoperative surgical angle measurement tool into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps make sure the tool is safe and effective while speeding up patient access to cool new tech. It affects device makers and hospitals, with the new rules effective July 24, 2026, and no big cost surprises expected.